Optimizing treatment for patients with anaplastic lymphoma kinase-positive lung cancer

Area of Science:

• Oncology
• Pharmacology
• Genetics

Background:

• Anaplastic lymphoma kinase (ALK) gene rearrangements are a key driver in a subset of non-small cell lung cancer (NSCLC).
• Significant advancements have been made in developing targeted therapies for ALK-positive NSCLC over the past nine years.

Purpose of the Study:

• To provide a comprehensive review of approved and investigational anaplastic lymphoma kinase (ALK) inhibitors for non-small cell lung cancer (NSCLC).
• To discuss common mechanisms of resistance to ALK inhibitors and emerging treatment controversies.

Main Methods:

• Literature review of approved and investigational ALK inhibitors.
• Analysis of resistance mechanisms and clinical trial data.
• Discussion of current treatment strategies and controversies in ALK-positive NSCLC.

Main Results:

• An expanding repertoire of ALK inhibitors demonstrates efficacy in ALK-positive NSCLC.
• Common resistance mechanisms to ALK inhibitors have been identified.
• Ongoing research is addressing challenges in first-line treatment selection and central nervous system metastases management.

Conclusions:

• Targeted therapy has revolutionized the treatment landscape for ALK-positive NSCLC.
• Understanding resistance mechanisms is crucial for optimizing treatment strategies.
• Further research is needed to address treatment controversies and improve patient outcomes.